Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
Amidst uncertainty regarding the safety of some integrase inhibitors during pregnancy, a study shows that an older integrase inhibitor may be a good option for those with HIV who intend to give birth.
The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.
Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.
Chewable raltegravir tablets can be crushed and stirred until dispersed in water, apple juice or breast milk and given to younger children according to WHO weight bands.
Analyzing the data after one year, researchers found that the new formulation of raltegravir (Isentress HD) was roughly equivalent in effectiveness and safety to the older formulation.
In late June 2017, Health Canada licensed the sale and use of a new formulation of the anti-HIV drug raltegravir (Isentress) as part of the treatment of HIV.